Stop imatinib or dasatinib study in CP-CML patients mainitaining complete molecular response for two years

Stop imatinib or dasatinib study in CP-CML patients mainitaining complete molecular response for two years - TWMU-TKI-STOP-Study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007944

Enrollment

Registered

2012-06-01

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic phase chronic myeloid leukemia

Interventions

After confirmation of CMR by RQ-PCR, imatinib is continuously administrated for two years. Then, treatment is ceased. After confirmation of CMR by RQ-PCR, dasatinib is continuously administrated fo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Patients 20years or more 2 CP-CML patients 3 No extramedullary diseases except for hepatosplenomegaly 4 Ph chromosome or its variant forms demonstrated by cytogenetic or FISH analyses 5 Undetectable BCR-ABL transcripts by Amp-CML for three months. Performance status 0-2 (ECOG) Preserved function of vital organs including liver, kidney, lung. Patients who agreed to participate this clinical trial, and signed to informed consent form.

Exclusion criteria

Exclusion criteria: 1 Active primary double cancers 2 Pregnant or breast-feeding women 3 Patients who are not considered apropriate candicdates for this clinical trial by the investigators, because of past history of diseases, co-morbidities, or other reasons.

Design outcomes

Primary

Measure	Time frame
Rate of CMR at 12 months after cessation of imatinib or dasatinib.	—

Countries

Japan

Contacts

Public ContactMasayuki Shiseki

Tokyo Women's Medical University Dept. Hematology

03-3353-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026